Biventricular Failure – Total Artificial Heart Francisco A. Arabía, MD Director, CHSI Center for Surgical Device Management Cedars-Sinai Heart Institute.

Slides:



Advertisements
Similar presentations
Presented By : Mahgul Gulzai ( ).  Introduction  History  Types of Artificial Heart  Why do we need Artificial Heart  Artificial Heart Surgery.
Advertisements

Assisted Circulation MEDICAL MEDICAL  Drugs  EECP MECHANICAL  IABP ( Introaortic balloon pump)  VAD (Ventricular assist device)
Right Heart Failure in Left Ventricular Assist Device Recipients
Right Ventricular Outflow Obstruction after Tetralogy of Fallot Repair Stephan Ziegeler, MD,* George J. Reul, MD,† Raymond F. Stainback, MD‡ *Department.
Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
Left Ventricular Assist Devices: The What and the Who Lance E. Sullenberger MD FACC FACP Capital Cardiology Associates.
ACHD Patients Should Receive Treatment in Adult Institutions Society of Thoracic Surgeons Adult Cardiac Surgery Database reports 39,872 adults undergoing.
Valvular heart surgery in Rajavithi hospital Dr.WITTAWAT PIBUL Rajavithi Hospital.
The Vexing Problem of Vasoplegia
The Big Puzzle Evolving the Continuum of Care. Agenda Goal Pre Acute Care Intra Hospital Care Post Hospital Care Grading the Value of Post Acute Providers.
Heart Transplantation for Patients with a Fontan Procedure
Ventricular Assist Devices Brian Schwartz, CCP February 25, 2003.
Rejection Normal response Inflammation 25% of pt. will have acute rejection during the first year post transplant Causes: Previous Rejection Noncompliance.
Advances In LVAD Patient Management
Introduction to Ventricular Assist Device (VAD)
Joseph G. Rogers, MD Professor of Medicine Duke University
Keith Aaronson, Mark Slaughter, Edwin McGee, William Cotts, Michael Acker, Mariell Jessup, Igor Gregoric, Pranav Loyalka, Valluvan Jeevanandam, Allen Anderson,
Periportal Fibrosis Without Cirrhosis Does Not Affect Outcomes Following Continuous Flow Ventricular Assist Device Implantation Jonathon E. Sargent, BS,
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Hemodialysis. Hemodialysis (also haemodialysis) is a method for removing waste products such as potassium and urea, as well as free water from the blood.
M Ruel, V Chan, M Boodhwani, B McDonald, X Ni, G Gill, K Lam, F Rubens, P Hendry, R Masters, T Mesana Ottawa, Canada How Detrimental is Re-Exploration.
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.
RDB Jaquiss Duke University
Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
How I would do my anterior VSD Closure
Fontan Procedure Ken Jusko, DO. Case 39 yo female with h/o tricuspid atresia and A. fib. and prior Fontan. No prior studies available for comparison.
Cardiothoracic Surgery. Topics Valvotomy and valve replacement Open heart surgery and cardiac bypass surgery Correction of congenital heart diseases Heart.
Acute Kidney Injury requiring renal replacement therapy increases mortality in patients undergoing Extracorporeal Membrane Oxygenation therapy. Divisions.
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical.
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children’s.
BME 301 Lecture Nineteen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
P. Leprince, CT Surgery Institut of cardiology Pitié-Salpétrière Group Paris, France The Total Artificial Heart Cardiowest: Indications and Results.
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director.
Concomitant Aortic Valve Repair in Patients Undergoing Continuous-flow Left Ventricular Assist Device Placement: A 10-year Experience and Clinical Implications.
BME 301 Lecture Nineteen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Extracorporeal Membrane Oxygenation for Bridge to Decision and to Recovery Shigeki Tabata, Hitoshi Hirose, Nicholas C. Cavarocchi, James T. Diehl, Hiroyuki.
Michael S Kiernan, MD, SM Assistant Professor, Tufts University Medical Director Ventricular Assist Device Program, Tufts Medical Center.
ECMO Extracorporeal membrane oxygenation
The SynCardia CardioWestTM Total Artificial Heart
James S. Tweddell, MD Warren W. Bailey Endowed Chair,
Current Surgical Standards for Mitral Leaflet and Chordal Repair: Patient Selection,Techniques and Clinical Outcomes CRT February 2011 Niv Ad, MD Chief,
Minimally Invasive Mitral Valve Repair
Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L
University of Chicago Medicine
Complications of left ventricular assist devices (LVADs)
Cardiovascular and Interventional Radiology
Ventricular function recovery on LVAD For idiopathic or ischemic CM
Preoperative screening for LVAD an TAH implantation
Assist Devices for the Treatment of Cardiogenic Shock
Is There a Need to Address AF in patients Undergoing Valve Surgery?
Role of ECMO in Acute Cardiogenic Shock
Mechanical circulatory support
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
Use of an Inexpensive Blue Band During Ventricular Assist Device and Total Artificial Heart Placement Facilitates and Expedites Explantation During Heart.
Update in Cardiac and Thoracic Surgery
Mechanical Circulatory Support Devices HOSEIN PASANDI.
Extracorporeal membrane oxygenation as a bridge to pulmonary transplantation  Charles W. Hoopes, MD, Jasleen Kukreja, MD, Jeffery Golden, MD, Daniel L.
Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011  William L.
William L. Holman, MD, James K. Kirklin, MD, David C
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

Biventricular Failure – Total Artificial Heart Francisco A. Arabía, MD Director, CHSI Center for Surgical Device Management Cedars-Sinai Heart Institute Los Angeles, CA Cedars-Sinai Heart Institute

Disclosures Surgical Proctor for Syncardia System Place more LVADs than TAHs

TAH-t

Not Everyone in Heart Failure needs a TAH But YOU need to know when your patient needs one. The Total Artificial Heart is NOT a Ventricular Assist Device. The TAH is a Heart REPLACEMENT Device

Newer Indications Biventricular Failure: Intermacs 1 & 2 Thrombosed Ventricles Failing Heart Transplant Graft Congenital Abnormalities Intractable Arrhythmias Progressive RVF in patient with LVAD Previous Multiple Cardiac Surgeries? Post Infarction VSD’s in BTT candidates Hypertrophic & Restrictive CM Cardiac Malignancies

CS experience with TAH 45 patients, 22% females Average age 53 (25 – 68) UNOS Status 1 A – 95% ECMO – 27% 45 patients, 22% females Average age 53 (25 – 68) UNOS Status 1 A – 95% ECMO – 27%

Etiology NICM 13 ICM (VSD) 10 (1) Familial 3 Valvular 3 Viral 1 NICM 13 ICM (VSD) 10 (1) Familial 3 Valvular 3 Viral 1 Restrictive CM 4 PGD 3 Amyloid 3 Arrhythmia 3 Chagas’ 1 Congenital 1 Restrictive CM 4 PGD 3 Amyloid 3 Arrhythmia 3 Chagas’ 1 Congenital 1

Risk - Intermacs Profiles Profile% of Population 111% 1 TCS27% 232% 2A8% 311% 3A3% 45% 4A3% 38% 40% 78%

Implantation Technique Remove Ventricles about 1 cm distal to AV Atrial quick connect with 1 suture line + repair Place prosthetic ventricles Measure & cut arterial conduits Anastomose arterial conduits Pressure Test Connect TAH, Off CPB

Implantation Technique To Close or not to Close? ECMO, Redo, Difficult – leave Sternum open First Sternotomy – Close? Bring back next Day Close if stable Prepare for transplant sternotomy!!!

Goals to Facilitate Explantation 1.Be able to perform Sternotomy with minimal risk 2.Obtain control of vascular structures 3.Remove device 4.True for all MCS patients undergoing Tx

Blue Bands Jaroszewski DE, Lackey JJ, Lanza LA, DeValeria PA, Arabia FA. Use of an inexpensive blue band during ventricular assist device and total artificial heart placement facilitates and expedites explantation during heart transplant. Ann Thorac Surg 2009 May; 87(5):

PTFE Cover

Silastic Membrane Surgical grade silicone membrane (0.060 Inches) Bentec Medical, Woodland CA

Silastic Membrane

Silastic Membrane Strip

Management Avoid Tamponade If chest closed at time of first operation: –Start anticoagulation 24 to 48 hours later if flows good. If chest open, hold anticoagulation for first few days. Greatest risk of bleeding in the first 2 WEEKS

Management Anticoagulation Usually start ASA 81 mg in the first 24 to 48 hours after chest closed. Start Heparin around 48 after chest closed. Start Coumadin Ambulation, Training and Discharge Start ASAP Transition to Freedom Driver Discharge Home Educate, Educate

Average LOS 58 days Average LOS post Tx – LVAD - 17 days Average LOS post TX – TAH - 18 days Average LOS 58 days Average LOS post Tx – LVAD - 17 days Average LOS post TX – TAH - 18 days Length of Stay Length of Support Average LOS (expired) 36.4 days Average LOS (Transplanted) 129 days Ongoing365+ days

Adverse Events ADVERSE EVENTS –Hepatic Dysfx 3 –Major Bleeding 40 –Major Infection 52 – Neuro Events (TIA) 7 –Renal Dysfx 11 –Stroke 11 (4 transplanted, 1 listed) – Cancer 1 – Psych 1 – Resp Failure 18 –DVT 1

Competing Outcomes at Cedars-Sinai 21 Alive On going Tx Deceased 100% 80% 60% 40% 20%

24

Conclusions TAH concept is for a very specific group of patients It is a for very ill population (Intermacs 1 & 2) Implementation has to be early, –BEFORE Multiple Organ Failure It is essential in the armamentarium for the management of end stage heart disease Future: Do re-TAH, use newer technology as it evolves. Easier than doing a re –Tx. TAH concept is for a very specific group of patients It is a for very ill population (Intermacs 1 & 2) Implementation has to be early, –BEFORE Multiple Organ Failure It is essential in the armamentarium for the management of end stage heart disease Future: Do re-TAH, use newer technology as it evolves. Easier than doing a re –Tx.

Coming Up DT Trial to start next month 50 cc TAH-t Trial to start in the next few months 5 Companies working in TAH technology, all pulsatile